ConductScience.org, home
SLC5A1: solute carrier family 5 member 1
API referenceFor AI assistants

Gene · 6523

Papers3,836

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

21 to 40 of 3,836

Download this page as JSON
TitleJournalYearPMIDFound bySource
Congenital glucose-galactose malabsorption due to SLC5A1 mutation: A case of hypernatraemic dehydration.J Pak Med Assoc202642160565PubTator, text miningPubMed
The mechanism of gut microbiota in septic cardiomyopathy based on the bulk transcriptome and Mendelian randomization analysis.Front Immunol202642158874PubTator, text miningPubMed
Mechanism of Fluid Reabsorption in Kidney Proximal Tubule: Interplay Between Lateral Na+/K+-ATPase and AQP1 and SGLT1 Mediated Water Fluxes.Acta Physiol (Oxf)202642153240PubTator, text miningPubMed
Sodium alginate-modified C3G nanoliposomes enhance their transport efficiency in 3D Caco-2 spheroid models through active transport mechanisms.Int J Biol Macromol202642114580PubTator, text miningPubMed
Combined analysis of metabolomics and transcriptomics reveals new indicators for the diagnosis and prognosis of colorectal cancer.Contemp Oncol (Pozn)202642089037PubTator, text miningPubMed
[Porcine epidemic diarrhea virus promotes self-replication by inducing reprogramming of glucose metabolism in host cells].Sheng Wu Gong Cheng Xue Bao202642009538PubTator, text miningPubMed
Molecular strategies for heterocyclic frameworks in antidiabetic drug discovery: a vision from 2020-2024.Future Med Chem202642003351PubTator, text miningPubMed
The effects of β-caryophyllene on butyrate utilization and metabolism in Caco-2 cells.Sci Rep202641922720PubTator, text miningPubMed
SGLT1 and SGLT2 Modulation in Antidiabetic Therapy-Comparative Insights into Gliflozins and Natural Compounds Resveratrol and Viniferin.Pharmaceuticals (Basel)202641901223PubTator, text miningPubMed
Vasculoprotective Effects of Sodium-Glucose Co-Transporter Inhibitors in Non-Diabetic Experimental Settings: A Narrative Review.Int J Mol Sci202641898437PubTator, text miningPubMed
Beyond Glycemia: Pharmacology-Driven Ketogenesis and Euglycemic DKA with SGLT2 Inhibitors-A Practical Review for Acute Care.J Pers Med202641893024PubTator, text miningPubMed
Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distributed Database study.BMJ Open Diabetes Res Care202641850718PubTator, text miningPubMed
Mendelian Randomization Analyses Indicate a Causal Association Between Sodium-Glucose Cotransporter-1 Inhibition and Mitochondrial Function.Curr Med Chem202641832709PubTator, text miningPubMed
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors.Eur J Clin Pharmacol202641811498PubTator, text miningPubMed
Repurposing SGLT2 Inhibitors for Cirrhotic Ascites: From Mechanistic Research to Clinical Exploration.J Clin Transl Hepatol202641810110PubTator, text miningPubMed
Increased Urinary Extracellular Vesicles and Reduced Expression of NEDD4L in Patients With Type 2 Diabetes and Diabetic Nephropathy.J Diabetes Res202641809111PubTator, text miningPubMed
Boscisucrophage: A Natural SGLT1/2 Inhibitor From Boscia senegalensis for Managing Type 2 Diabetes.Food Sci Nutr202641804342PubTator, text miningPubMed
Maternal docosahexaenoic acid and eicosapentaenoic acid supplementation: effects and mechanisms on lipid metabolism in the offspring.Front Nutr202641798834PubTator, text miningPubMed
Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease.Front Physiol202641797844PubTator, text miningPubMed
Beneficial Effects of Canagliflozin in Heart Failure Associated With Cardiac and Surgical Procedures.Rev Cardiovasc Med202641789314PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Previous pageNext page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/6523/papers?page=2

API referenceFor AI assistants